| Title | Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis |
| Authors | Zhao, Fuxing Huo, Xingfa Wang, Miaozhou Liu, Zhen Zhao, Yi Ren, Dengfeng Xie, Qiqi Liu, Zhilin Li, Zitao Du, Feng Shen, Guoshuang Zhao, Jiuda |
| Affiliation | Qinghai Univ, Affiliated Hosp, Breast Dis Diag & Treatment Ctr, Xining, Peoples R China Qinghai Univ, Affiliated Canc Hosp, Xining, Peoples R China Peking Univ, Med Dept, VIPII Gastrointestinal Canc Div, Minist Educ,Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China |
| Keywords | TUMOR-INFILTRATING LYMPHOCYTES PHASE-II OPEN-LABEL PLUS TRASTUZUMAB PIK3CA MUTATIONS FREE SURVIVAL HER2-TARGETED THERAPY CHEMOTHERAPY PLUS ANTI-HER2 THERAPY RECEPTOR STATUS |
| Issue Date | 28-Oct-2021 |
| Publisher | FRONTIERS IN ONCOLOGY |
| Abstract | Introduction: The predictive strength and accuracy of some biomarkers for the pathological complete response (pCR) to neoadjuvant therapy for HER2-positive breast cancer remain unclear. This study aimed to compare the accuracy of the HER2-enriched subtype and the presence of PIK3CA mutations, namely, TILs, HRs, and Ki-67, in predicting the pCR to HER2-positive breast cancer therapy. Methods: We screened studies that included pCR predicted by one of the following biomarkers: the HER2-enriched subtype and the presence of PIK3CA mutations, TILs, HRs, or Ki-67. We then calculated the pooled sensitivity, specificity, positive and negative predictive values (PPVs and NPVs, respectively), and positive and negative likelihood ratios (LRs). Summary receiver operating characteristic (SROC) curves and areas under the curve (AUCs) were used to estimate the diagnostic accuracy. Results:& nbsp;The pooled estimates of sensitivity and specificity for the HER2-enriched subtype and the presence of PIK3CA mutations, namely, TILs, HRs, and Ki-67, were 0.66 and 0.62, 0.85 and 0.27, 0.49 and 0.61, 0.54 and 0.64, and 0.68 and 0.51, respectively. The AUC of the HER2-enriched subtype was significantly higher (0.71) than those for the presence of TILs (0.59, p = 0.003), HRs (0.65, p = 0.003), and Ki-67 (0.62, p = 0.005). The AUC of the HER2-enriched subtype had a tendency to be higher than that of the presence of PIK3CA mutations (0.58, p = 0.220). Moreover, it had relatively high PPV (0.58) and LR+ (1.77), similar NPV (0.73), and low LR- (0.54) compared with the other four biomarkers. Conclusions: The HER2-enriched subtype has a moderate breast cancer diagnostic accuracy, which is better than those of the presence of PIK3CA mutations, TILs, HRs, and Ki-67. |
| URI | http://hdl.handle.net/20.500.11897/629369 |
| ISSN | 2234-943X |
| DOI | 10.3389/fonc.2021.731148 |
| Indexed | SCI(E) |
| Appears in Collections: | 待认领 |
